{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:11:15Z","timestamp":1791569475892,"version":"4.3.4"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Talent Program for High-throughput Sequencing Technology in Infectious Diseases, China","award":["MTP2022B020"],"award-info":[{"award-number":["MTP2022B020"]}]},{"name":"R&D Program of the Beijing Municipal Education Commission, China","award":["KM202210025004"],"award-info":[{"award-number":["KM202210025004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00739-3","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T10:45:23Z","timestamp":1744281923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A bibliometric analysis of HIV-1 drug-resistant minority variants from 1999 to 2024"],"prefix":"10.1186","volume":"22","author":[{"given":"Chang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanxi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"739_CR1","unstructured":"UNAIDS [Internet]. [cited 2023 Sep 16]. Available from: https:\/\/www.unaids.org\/en"},{"key":"739_CR2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.315.7117.1194","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ. 1997;315:1194\u20139.","journal-title":"BMJ"},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1099\/0022-1317-79-6-1337","volume":"79","author":"LM Mansky","year":"1998","unstructured":"Mansky LM. Retrovirus mutation rates and their role in genetic variation. J Gen Virol. 1998;79:1337\u201345.","journal-title":"J Gen Virol"},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483\u20139.","journal-title":"Science"},{"key":"739_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1099\/jgv.0.001026","volume":"99","author":"D Ghimire","year":"2018","unstructured":"Ghimire D, Rai M, Gaur R. Novel host restriction factors implicated in HIV-1 replication. J Gen Virol. 2018;99:435\u201346.","journal-title":"J Gen Virol"},{"key":"739_CR6","doi-asserted-by":"crossref","unstructured":"Clavel F. HIV Drug Resistance. The New England Journal of Medicine. 2004.","DOI":"10.1056\/NEJM2ra025195"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"e0026922","DOI":"10.1128\/mbio.00269-22","volume":"13","author":"SA Kemp","year":"2022","unstructured":"Kemp SA, Charles OJ, Derache A, Smidt W, Martin DP, Iwuji C, et al. HIV-1 evolutionary dynamics under nonsuppressive antiretroviral therapy. Mbio. 2022;13:e0026922.","journal-title":"Mbio"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1742-4690-11-56","volume":"11","author":"A Pandit","year":"2014","unstructured":"Pandit A, de Boer RJ. Reliable reconstruction of HIV-1 whole genome haplotypes reveals clonal interference and genetic hitchhiking among immune escape variants. Retrovirology. 2014;11:56.","journal-title":"Retrovirology"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1126\/science.7824947","volume":"267","author":"JM Coffin","year":"1995","unstructured":"Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Sci (n Y NY). 1995;267:483\u20139.","journal-title":"Sci (n Y NY)"},{"key":"739_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/QAD.0b013e3282f29478","volume":"22","author":"M Kearney","year":"2008","unstructured":"Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, Mican J, et al. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. Aids. 2008;22:497\u2013501.","journal-title":"Aids"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/01.aids.0000216370.69066.7f","volume":"20","author":"S Palmer","year":"2006","unstructured":"Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS (lond Engl). 2006;20:701\u201310.","journal-title":"AIDS (lond Engl)"},{"key":"739_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jviromet.2007.06.012","volume":"146","author":"R Paredes","year":"2007","unstructured":"Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and Env resistance mutations. J Virol Methods. 2007;146:136\u201346.","journal-title":"J Virol Methods"},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1086\/596736","volume":"199","author":"BB Simen","year":"2009","unstructured":"Simen BB, Simons JF, Hullsiek KH, Novak RM, MacArthur RD, Baxter JD, et al. Low-Abundance Drug-Resistant viral variants in chronically HIV-Infected, antiretroviral treatment\u2013Naive patients significantly impact treatment outcomes. J Infect Dis. 2009;199:693\u2013701.","journal-title":"J Infect Dis"},{"key":"739_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jama.2011.375","volume":"305","author":"JZ Li","year":"2011","unstructured":"Li JZ, Low-Frequency. HIV-1 drug resistance mutations and risk of NNRTI-Based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA. 2011;305:1327.","journal-title":"JAMA"},{"key":"739_CR15","unstructured":"Consolidated. guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach [Internet]. [cited 2024 May 7]. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240031593"},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","volume":"43","author":"S Palmer","year":"2005","unstructured":"Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in Treatment-Experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43:406\u201313.","journal-title":"J Clin Microbiol"},{"key":"739_CR17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1097\/QAD.0000000000000748","volume":"29","author":"M Casadell\u00e0","year":"2015","unstructured":"Casadell\u00e0 M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, P\u00e9rez-\u00c1lvarez S, et al. Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. AIDS (Lond Engl). 2015;29:1493\u2013504.","journal-title":"AIDS (Lond Engl)"},{"key":"739_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1086\/595703","volume":"48","author":"KJ Metzner","year":"2009","unstructured":"Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, et al. Minority quasispecies of Drug-Resistant HIV\u20101 that lead to early therapy failure in Treatment\u2010Naive and \u2010Adherent patients. Clin Infect Dis. 2009;48:239\u201347.","journal-title":"Clin Infect Dis"},{"key":"739_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jama.2011.375","volume":"305","author":"JZ Li","year":"2011","unstructured":"Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA. 2011;305:1327\u201335.","journal-title":"JAMA"},{"key":"739_CR20","doi-asserted-by":"publisher","first-page":"1452303","DOI":"10.3389\/fimmu.2024.1452303","volume":"15","author":"R Zhang","year":"2024","unstructured":"Zhang R, Jiang Q, Zhuang Z, Zeng H, Li Y. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus. Front Immunol. 2024;15:1452303.","journal-title":"Front Immunol"},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"e39295","DOI":"10.1097\/MD.0000000000039295","volume":"103","author":"F Tang","year":"2024","unstructured":"Tang F, Zhao F, Jiang Y, Zhang T, Wang B. Global hotspots and trends in diabetic peripheral neuropathy research from 2011 to 2023. Med (Baltim). 2024;103:e39295.","journal-title":"Med (Baltim)"},{"key":"739_CR22","doi-asserted-by":"crossref","unstructured":"Deng J, Qin Y. Current status, hotspots, and prospects of artificial intelligence in ophthalmology: A bibliometric analysis (2003\u20132023). Ophthalmic Epidemiol. 2024;1\u201314.","DOI":"10.1080\/09286586.2024.2373956"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1109\/TEM.2018.2870648","volume":"67","author":"G Marzi","year":"2020","unstructured":"Marzi G, Caputo A, Garces E, Dabi\u0107 M. A three decade mixed-method bibliometric investigation of the IEEE transactions on engineering management. IEEE Trans Eng Manage. 2020;67:4\u201317.","journal-title":"IEEE Trans Eng Manage"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11657-021-00929-2","volume":"16","author":"H Wu","year":"2021","unstructured":"Wu H, Li Y, Tong L, Wang Y, Sun Z. Worldwide research tendency and hotspots on hip fracture: A 20-year bibliometric analysis. Arch Osteoporos. 2021;16:73.","journal-title":"Arch Osteoporos"},{"key":"739_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ssci.2019.06.022","volume":"120","author":"Y Yang","year":"2019","unstructured":"Yang Y, Reniers G, Chen G, Goerlandt F. A bibliometric review of laboratory safety in universities. Saf Sci. 2019;120:14\u201324.","journal-title":"Saf Sci"},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11:959\u201375.","journal-title":"J Informetr"},{"key":"739_CR27","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3390\/polym14163297","volume":"14","author":"W Chiari","year":"2022","unstructured":"Chiari W, Damayanti R, Harapan H, Puspita K, Saiful S, Rahmi R, et al. Trend of polymer research related to COVID-19 pandemic: bibliometric analysis. Polymers. 2022;14:3297.","journal-title":"Polymers"},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.virusres.2016.10.019","volume":"239","author":"M Casadell\u00e0","year":"2017","unstructured":"Casadell\u00e0 M, Paredes R. Deep sequencing for HIV-1 clinical management. Virus Res. 2017;239:69\u201381.","journal-title":"Virus Res"},{"key":"739_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/QAD.0000000000002134","volume":"33","author":"RS Milne","year":"2019","unstructured":"Milne RS, Silverman RA, Beck IA, Mckernan-Mullin J, Deng W, Sibley TR, et al. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women. AIDS. 2019;33:941\u201351.","journal-title":"AIDS"},{"key":"739_CR30","doi-asserted-by":"publisher","first-page":"e0345422","DOI":"10.1128\/spectrum.03454-22","volume":"10","author":"V Novitsky","year":"2022","unstructured":"Novitsky V, Nyandiko W, Vreeman R, DeLong AK, Manne A, Scanlon M, et al. Added value of next generation over Sanger sequencing in Kenyan youth with extensive HIV-1 drug resistance. Microbiol Spectr. 2022;10:e0345422.","journal-title":"Microbiol Spectr"},{"key":"739_CR31","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1101\/gr.6468307","volume":"17","author":"C Wang","year":"2007","unstructured":"Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007;17:1195\u2013201.","journal-title":"Genome Res"},{"key":"739_CR32","doi-asserted-by":"publisher","first-page":"e83150","DOI":"10.1371\/journal.pone.0083150","volume":"8","author":"M Nishizawa","year":"2013","unstructured":"Nishizawa M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, et al. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan. PLoS ONE. 2013;8:e83150.","journal-title":"PLoS ONE"},{"key":"739_CR33","doi-asserted-by":"publisher","first-page":"e21655","DOI":"10.1371\/journal.pone.0021655","volume":"6","author":"P Delobel","year":"2011","unstructured":"Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS ONE. 2011;6:e21655.","journal-title":"PLoS ONE"},{"key":"739_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1086\/655397","volume":"202","author":"S Gianella","year":"2010","unstructured":"Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis. 2010;202:657.","journal-title":"J Infect Dis"},{"key":"739_CR35","doi-asserted-by":"crossref","unstructured":"Sili U, Aksu B, Tekin A, Hasdemir U, Soyletir G, Korten V. Assessment of transmitted HIV-1 drug resistance mutations using ultra- deep pyrosequencing in a Turkish cohort. Curr HIV Res. 16:216\u201321.","DOI":"10.2174\/1570162X16666180910130112"},{"key":"739_CR36","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/jac\/dkr354","volume":"66","author":"C Alteri","year":"2011","unstructured":"Alteri C, Santoro MM, Abbate I, Rozera G, Bruselles A, Bartolini B, et al. Sentinel mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing. J Antimicrob Chemother. 2011;66:2615\u201323.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1468-1293.2012.01037.x","volume":"14","author":"M Pingen","year":"2013","unstructured":"Pingen M, van der Ende M, Wensing A, el Barzouhi A, Simen B, Schutten M, et al. Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations. HIV Med. 2013;14:176\u201381.","journal-title":"HIV Med"},{"key":"739_CR38","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1093\/jac\/dkx232","volume":"72","author":"EK Alidjinou","year":"2017","unstructured":"Alidjinou EK, Deldalle J, Hallaert C, Robineau O, Ajana F, Choisy P, et al. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients. J Antimicrob Chemother. 2017;72:2823\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR39","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/jmv.25224","volume":"90","author":"F Nicot","year":"2018","unstructured":"Nicot F, Jeanne N, Raymond S, Delfour O, Carcenac R, Lefebvre C, et al. Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene. J Med Virol. 2018;90:1486\u201392.","journal-title":"J Med Virol"},{"key":"739_CR40","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/JCM.00105-18","volume":"56","author":"PL Tzou","year":"2018","unstructured":"Tzou PL, Ariyaratne P, Varghese V, Lee C, Rakhmanaliev E, Villy C, et al. Comparison of an in vitro diagnostic Next-Generation sequencing assay with Sanger sequencing for HIV-1 genotypic resistance testing. J Clin Microbiol. 2018;56:e00105\u201318.","journal-title":"J Clin Microbiol"},{"key":"739_CR41","doi-asserted-by":"publisher","first-page":"20166","DOI":"10.1073\/pnas.1110064108","volume":"108","author":"CB Jabara","year":"2011","unstructured":"Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R. Accurate sampling and deep sequencing of the HIV-1 protease gene using a primer ID. Proc Natl Acad Sci USA. 2011;108:20166\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"739_CR42","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1016\/S2352-3018(16)30119-9","volume":"3","author":"S \u00c1vila-R\u00edos","year":"2016","unstructured":"\u00c1vila-R\u00edos S, Garc\u00eda-Morales C, Mat\u00edas-Florentino M, Romero-Mora KA, Tapia-Trejo D, Quiroz-Morales VS, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: A nationally representative 2015 WHO survey. Lancet HIV. 2016;3:e579\u201391.","journal-title":"Lancet HIV"},{"key":"739_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jviromet.2016.11.008","volume":"240","author":"M Huber","year":"2017","unstructured":"Huber M, Metzner KJ, Geissberger FD, Shah C, Leemann C, Klimkait T, et al. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. J Virol Methods. 2017;240:7\u201313.","journal-title":"J Virol Methods"},{"key":"739_CR44","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/s41598-020-58544-z","volume":"10","author":"ER Lee","year":"2020","unstructured":"Lee ER, Parkin N, Jennings C, Brumme CJ, Enns E, Casadella M, et al. Performance comparison of next generation sequencing analysis pipelines for HIV-1 drug resistance testing. Sci Rep. 2020;10:1634.","journal-title":"Sci Rep"},{"key":"739_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jviromet.2018.08.001","volume":"261","author":"DE Kireev","year":"2018","unstructured":"Kireev DE, Lopatukhin AE, Murzakova A, Pimkina E, Speranskaya AS, Neverov AD, et al. Evaluating the accuracy and sensitivity of detecting minority HIV-1 populations by illumina next-generation sequencing. J Virol Methods. 2018;261:40\u20135.","journal-title":"J Virol Methods"},{"key":"739_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/QAI.0b013e3182515730","volume":"60","author":"DA Lehman","year":"2012","unstructured":"Lehman DA, Wanalwa DC, McCoy CO, Matsen FA, Langat A, Chohan BH, et al. Low-frequency nevirapine resistance at multiple sites May predict treatment failure in infants on nevirapine-based treatment. J Acquir Immune Defic Syndr. 2012;60:225.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"739_CR47","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/01.aids.0000222071.60620.1d","volume":"20","author":"S Loubser","year":"2006","unstructured":"Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20:995\u20131002.","journal-title":"AIDS"},{"key":"739_CR48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1086\/596486","volume":"48","author":"A Coovadia","year":"2009","unstructured":"Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis. 2009;48:462\u201372.","journal-title":"Clin Infect Dis"},{"key":"739_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/aid.2009.0082","volume":"26","author":"CF Rowley","year":"2010","unstructured":"Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, Essex M, et al. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses. 2010;26:293\u2013300.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"739_CR50","doi-asserted-by":"crossref","unstructured":"Milne RS, Silverman RA, Beck IA, Mckernan-Mullin J, Deng W, Sibley TR et al. Minority and majority pre-treatment HIV-1 drug resistance associated with failure of 1st-line NNRTI ART in kenyan women. AIDS (London, England). 2019;10.1097\/QAD.0000000000002134.","DOI":"10.1097\/QAD.0000000000002134"},{"key":"739_CR51","first-page":"672","volume":"201","author":"EK Halvas","year":"2010","unstructured":"Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. J Infect Dis. 2010;201:672\u201380.","journal-title":"J Infect Dis"},{"key":"739_CR52","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/jac\/dky561","volume":"74","author":"B Su","year":"2019","unstructured":"Su B, Zheng X, Liu Y, Liu L, Xin R, Lu H, et al. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes. J Antimicrob Chemother. 2019;74:1408\u201316.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jcv.2014.10.020","volume":"62","author":"F Nicot","year":"2015","unstructured":"Nicot F, Saun\u00e9 K, Raymond S, Jeanne N, Carcenac R, Lefebvre C, et al. Minority resistant HIV-1 variants and the response to first-line NNRTI therapy. J Clin Virol. 2015;62:20\u20134.","journal-title":"J Clin Virol"},{"key":"739_CR54","doi-asserted-by":"publisher","first-page":"e00769","DOI":"10.1128\/JVI.00769-17","volume":"91","author":"A Chaillon","year":"2017","unstructured":"Chaillon A, Nakazawa M, Wertheim JO, Little SJ, Smith DM, Mehta SR, et al. No substantial evidence for sexual transmission of minority HIV drug resistance mutations in men who have sex with men. J Virol. 2017;91:e00769\u201317.","journal-title":"J Virol"},{"key":"739_CR55","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/infdis\/jit310","volume":"208","author":"KJ Metzner","year":"2013","unstructured":"Metzner KJ, Scherrer AU, Preiswerk B, Joos B, von Wyl V, Leemann C, et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis. 2013;208:1102\u201312.","journal-title":"J Infect Dis"},{"key":"739_CR56","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1371\/journal.pmed.0050158","volume":"5","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Li J-F, Wei X, Lipscomb J, Irlbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLos Med. 2008;5:1112\u201322.","journal-title":"PLos Med"},{"key":"739_CR57","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.3390\/v6093428","volume":"6","author":"S Gupta","year":"2014","unstructured":"Gupta S, Lataillade M, Kyriakides TC, Chiarella J, John EPS, Webb S, et al. Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-na\u00efve subjects. Viruses. 2014;6:3428.","journal-title":"Viruses"},{"key":"739_CR58","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72:e1\u201325.","journal-title":"Drugs"},{"key":"739_CR59","doi-asserted-by":"publisher","first-page":"e10952","DOI":"10.1371\/journal.pone.0010952","volume":"5","author":"M Lataillade","year":"2010","unstructured":"Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-na\u00efve subjects in the CASTLE study. PLoS ONE. 2010;5:e10952.","journal-title":"PLoS ONE"},{"key":"739_CR60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/jac\/dkx366","volume":"73","author":"M Perrier","year":"2018","unstructured":"Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, et al. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing Darunavir or Atazanavir. J Antimicrob Chemother. 2018;73:173\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1089\/aid.2009.0189","volume":"26","author":"LL Ross","year":"2010","unstructured":"Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, et al. Impact of low abundance HIV variants on response to Ritonavir-Boosted Atazanavir or Fosamprenavir given once daily with Tenofovir\/Emtricitabine in Antiretroviral-Naive HIV-Infected patients. AIDS Res Hum Retroviruses. 2010;26:407\u201317.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"739_CR62","doi-asserted-by":"crossref","unstructured":"Gibson RM, Weber J, Winner D, Miller MD, Qui\u00f1ones-Mateu ME. Contribution of Human Immunodeficiency Virus Type 1 Minority Variants to Reduced Drug Susceptibility in Patients on an Integrase Strand Transfer Inhibitor-Based Therapy. Sluis-Cremer N, editor. PLoS ONE. 2014;9:e104512.","DOI":"10.1371\/journal.pone.0104512"},{"key":"739_CR63","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jac\/dky005","volume":"73","author":"SC Inzaule","year":"2018","unstructured":"Inzaule SC, Hamers RL, Noguera-Julian M, Casadell\u00e0 M, Parera M, De Rinke TF, et al. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa. J Antimicrob Chemother. 2018;73:1167\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR64","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1093\/jac\/dkaa309","volume":"75","author":"JL Mbisa","year":"2020","unstructured":"Mbisa JL, Ledesma J, Kirwan P, Bibby DF, Manso C, Skingsley A, et al. Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK. J Antimicrob Chemother. 2020;75:3311\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR65","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/hiv.13038","volume":"22","author":"J Baxter","year":"2021","unstructured":"Baxter J, Dunn D, Tostevin A, Marvig R, Bennedb\u00e6k M, Cozzi-Lepri A, et al. Transmitted HIV\u20101 drug resistance in a large international cohort using next\u2010generation sequencing: results from the strategic timing of antiretroviral treatment (START) study. HIV Med. 2021;22:360\u201371.","journal-title":"HIV Med"},{"key":"739_CR66","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/infdis\/jir821","volume":"205","author":"D Armenia","year":"2012","unstructured":"Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D\u2019Arrigo R, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: A refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis. 2012;205:557\u201367.","journal-title":"J Infect Dis"},{"key":"739_CR67","doi-asserted-by":"publisher","first-page":"e0172206","DOI":"10.1371\/journal.pone.0172206","volume":"12","author":"ME Abram","year":"2017","unstructured":"Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, et al. Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS ONE. 2017;12:e0172206.","journal-title":"PLoS ONE"},{"key":"739_CR68","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1093\/jac\/dky198","volume":"73","author":"T Nguyen","year":"2018","unstructured":"Nguyen T, Fofana DB, L\u00ea MP, Charpentier C, Peytavin G, Wirden M, et al. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. J Antimicrob Chemother. 2018;73:2485\u201392.","journal-title":"J Antimicrob Chemother"},{"key":"739_CR69","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jcv.2015.11.009","volume":"73","author":"J Fonager","year":"2015","unstructured":"Fonager J, Larsson JT, Hussing C, Neess Engsig F, Nielsen C, Fischer TK. Identification of minority resistance mutations in the HIV-1 integrase coding region using next generation sequencing. J Clin Virology: Official Publication Pan Am Soc Clin Virol. 2015;73:95\u2013100.","journal-title":"J Clin Virology: Official Publication Pan Am Soc Clin Virol"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00739-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:59:11Z","timestamp":1744289951000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00739-3","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency declarations"}}],"article-number":"47"}}